Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

Journal of the American Academy of Dermatology

Volumn 80, Issue 4, 2019, Pages 913-921.e9

  Guttman Yassky, Emma ^a   Silverberg, Jonathan I ^b,c   Nemoto, Osamu ^d   Forman, Seth B ^e   Wilke, August ^f   Prescilla, Randy ^f   de la Peña, Amparo ^f   Nunes, Fabio P ^f   Janes, Jonathan ^f   Gamalo, Margaret ^f   Donley, David ^g   Paik, Jim ^f   DeLozier, Amy M ^f   Nickoloff, Brian J ^f   Simpson, Eric L ^h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Northwestern University Feinberg School of Medicine   (United States)

^d Sapporo Skin Clinic   (Japan)

^e Forward Clinical Trials   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g EMB Statistical Solutions   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

atopic dermatitis; baricitinib; EASI; JAK STAT signaling; phase 2; pruritus; SCORAD; topical corticosteroids

Indexed keywords

BARICITINIB; CREATINE KINASE; TRIAMCINOLONE; AZETIDINE DERIVATIVE; CORTICOSTEROID; DERMATOLOGICAL AGENT; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; SULFONAMIDE;

ADULT; ARTICLE; ATOPIC DERMATITIS; CELLULITIS; CONTROLLED STUDY; CYSTITIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ECZEMA AREA AND SEVERITY INDEX; FEMALE; HEADACHE; HUMAN; INFECTION; INTESTINE POLYP; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PLATELET COUNT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SKIN ABSCESS; SLEEP DEBT; STAPHYLOCOCCUS INFECTION; TINEA CORPORIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRAL CONJUNCTIVITIS; WOUND INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CUTANEOUS DRUG ADMINISTRATION; DRUG ADMINISTRATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ADULT; AZETIDINES; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME;

EID: 85061652608     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2018.01.018     Document Type: Article

References (27)

1. Brunner, P.M., Guttman-Yassky, E., Leung, D.Y., The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol 139:4S (2017), S65–S76.
2. Schmitt, J., Langan, S., Deckert, S., et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 132:6 (2013), 1337–1347.
3. Silverberg, J.I., Public health burden and epidemiology of atopic dermatitis. Dermatol Clin 35:3 (2017), 283–289.
4. Bieber, T., Akdis, C., Lauener, R., et al. Global Allergy Forum and 3rd Davos Declaration 2015: atopic dermatitis/eczema: challenges and opportunities toward precision medicine. Allergy 71:5 (2016), 588–592.
5. Mei-Yen, Y.A., Tay, Y.K., Atopic dermatitis: racial and ethnic differences. Dermatol Clin 35:3 (2017), 395–402.
6. Wollenberg, A., Oranje, A., Deleuran, M., et al. ETFAD/EADV Eczema Task Force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 30:5 (2016), 729–747.
7. Fridman, J.S., Scherle, P.A., Collins, R., et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:9 (2010), 5298–5307.
8. Politiek, K., van der Schaft, J., Coenraads, P.J., de Bruin-Weller, M.S., Schuttelaar, M.L., Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis. Br J Dermatol 174:1 (2016), 201–203.
9. van der Schaft, J., Politiek, K., van den Reek, J.M., et al. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 172:6 (2015), 1621–1627.
10. Simpson, E.L., Bieber, T., Guttman-Yassky, E., et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375:24 (2016), 2335–2348.
11. Blauvelt, A., de Bruin-Weller, M., Gooderham, M., et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:10086 (2017), 2287–2303.
12. Hanifin, J.M., Rajka, G., Diagnositic features of atopic dermatitis. Acta DermatoVenerologica (Stockholm) 92:Suppl (1980), 44–47.
13. Hanifin, J.M., Thurston, M., Omoto, M., Cherill, R., Tofte, S.J., Graeber, M., The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 10:1 (2001), 11–18.
14. Kunz, B., Oranje, A.P., Labreze, L., Stalder, J.F., Ring, J., Taieb, A., Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 195:1 (1997), 10–19.
15. Finlay, A.Y., Khan, G.K., Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19:3 (1994), 210–216.
16. Charman, C.R., Venn, A.J., Williams, H.C., The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 140:12 (2004), 1513–1519.
17. Beck, L.A., Thaci, D., Hamilton, J.D., et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:2 (2014), 130–139.
18. Bissonnette, R., Papp, K.A., Poulin, Y., et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 175:5 (2016), 902–911.
19. Yamaoka, K., Benefit and risk of tofacitinib in the treatment of rheumatoid arthritis: a focus on herpes zoster. Drug Saf 39:9 (2016), 823–840.
20. Ruzicka, T., Mihara, R., Anti-interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med, 376(21), 2017, 2093.
21. Oetjen, L.K., Mack, M.R., Feng, J., et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 171:1 (2017), 217–228.e13.
22. Wilson, S.R., Thé L., Batia, L.M., et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 155:2 (2013), 285–295.
23. Fleischmann, R., Schiff, M., van der Heijde, D., et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:3 (2017), 506–517.
24. Taylor, P.C., Keystone, E.C., van der Heijde, D., et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376:7 (2017), 652–662.
25. Dougados, M., van der Heijde, D., Chen, Y.C., et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76:1 (2017), 88–95.
26. Genovese, M.C., Kremer, J., Zamani, O., et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:13 (2016), 1243–1252.
27. Papp, K.A., Menter, M.A., Abe, M., et al. OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 173:4 (2015), 949–961.